Sustainable reimbursement is key for medical AI to scale and benefit patients. A new Policy Corner article by Michael D Abramoff, Tinglong Dai, and James Zou explores fee-for-service and value-based care payment models for the use of medical AI. nejm.ai/445c5JT

Is #ChatGPT corrupting peer review?

Thought-provoking nature article on our recent finding that paper reviews are being written by #LLMs nature.com/articles/d4158…

Sustainable reimbursement is key for medical AI to scale and benefit patients. A new Policy Corner article by Michael D Abramoff, Tinglong Dai, and James Zou explores fee-for-service and value-based care payment models for the use of medical AI. nejm.ai/445c5JT

Policy Corner: Scaling Adoption of Medical AI — Reimbursement from Value-Based Care and Fee-for-Service Perspectives nejm.ai/445c5JT

How to get paid is increasingly the biggest puzzle facing biomedical #AI -- more so than developing the technology. Our new NEJM AI article discusses the economics of medical AI + payment landscape ai.nejm.org/stoken/default…

Real pleasure writing this w/ Michael D Abramoff and

Great work by Hani Goodarzi Babak Alipanahi, Fereydoun Hormozdiari and the exai bio team!

I have been thinking about the best approaches for building predictive models in liquid biopsies for many years now! Orion, which was built by the exai bio team with input from our advisors Olivier Elemento and James Zou is the culmination of that effort. medrxiv.org/content/10.110…

How to get paid is increasingly the biggest puzzle facing biomedical #AI -- more so than developing the technology. Our new NEJM AI article discusses the economics of medical AI + payment landscape ai.nejm.org/stoken/default…

Real pleasure writing this w/ Michael D Abramoff and

If we want to accelerate scaling AI for the benefit of patients and populations, reimbursement of some form is key. Healthcare finances are complex, to say the least, so it is hard for AI creators - and for any stakeholder really - to figure out where to start. Hopefully my paper

How to pick a problem. Today in Cell. 1/53
cell.com/cell/fulltext/…

Can generative AI help us develop new drugs? Stanford HAI faculty affiliate James Zou co-developed SyntheMol, a model that creates recipes for chemists to synthesize drugs in the lab. stan.md/3JdqXw9

Thank you Stanford HAI for highlighting our work!

What (open) LLMs are clinicians using on a day-to-day basis?

Please comment if something else! If you select 'finetuned/specialized LLM', please also comment which one 🙂

(I have another poll for proprietary/closed LLMs, see second post ⬇️)

Excited to visit UT Austin today and thanks to Ying Ding for hosting! ifml.institute/events/ifml-de…

Thank you Stanford University for highlighting our work on #genAI for designing new molecules and drugs! med.stanford.edu/news/all-news/…

Nice blog post about our new ADMET-AI platform by Kyle Swanson portal.valencelabs.com/blogs/post/adm…